These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

83 related articles for article (PubMed ID: 24195247)

  • 1. [Refractory anemias].
    Efira A; Azerad MA
    Rev Med Brux; 2013 Sep; 34(4):323-7. PubMed ID: 24195247
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Myelodysplastic syndromes. Diagnosis and therapeutic strategies].
    Aul C; Giagounidis A; Germing U; Ganser A
    Med Klin (Munich); 2002 Nov; 97(11):666-76. PubMed ID: 12434275
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Combined stratification of refractory anemia according to both WHO and IPSS criteria has a prognostic impact and improves identification of patients who may benefit from stem cell transplantation.
    Cermák J; Vítek A; Michalová K
    Leuk Res; 2004 Jun; 28(6):551-7. PubMed ID: 15120930
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Refractory anemia and the myelodysplastic syndromes.
    Lawrence LW
    Clin Lab Sci; 2004; 17(3):178-86. PubMed ID: 15314893
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Myelodysplastic syndrome].
    Urabe A
    Gan To Kagaku Ryoho; 2005 Mar; 32(3):287-91. PubMed ID: 15791810
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Bone marrow transplantation from HLA-identical siblings as first-line treatment in patients with myelodysplastic syndromes: early transplantation is associated with improved outcome. Chronic Leukemia Working Party of the European Group for Blood and Marrow Transplantation.
    Runde V; de Witte T; Arnold R; Gratwohl A; Hermans J; van Biezen A; Niederwieser D; Labopin M; Walter-Noel MP; Bacigalupo A; Jacobsen N; Ljungman P; Carreras E; Kolb HJ; Aul C; Apperley J
    Bone Marrow Transplant; 1998 Feb; 21(3):255-61. PubMed ID: 9489648
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Myelodysplastic syndromes: a community hospital-based study of prognostic factors and International Prognostic Scoring System.
    Mirza I; Garzón R; Burns J; Edwards L; Fernandez-Cymering C; Kloss R
    Conn Med; 2001 Aug; 65(8):455-63. PubMed ID: 11550445
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Myelodysplastic syndromes or refractory anemias].
    Fenaux P
    Rev Prat; 1993 Jun; 43(11):1379-85. PubMed ID: 8235387
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Detection of risk groups in myelodysplastic syndromes. A multicenter study.
    Belli C; Acevedo S; Bengio R; Arrossagaray G; Watman N; Rossi N; García J; Flores G; Goldztein S; Larripa I
    Haematologica; 2002 Jan; 87(1):9-16. PubMed ID: 11801460
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Intensive chemotherapy for patients with high-risk myelodysplastic syndrome.
    Beran M
    Int J Hematol; 2000 Aug; 72(2):139-50. PubMed ID: 11039661
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparison of five prognostic scoring systems, the French-American-British (FAB) and World Health Organization (WHO) classifications in patients with myelodysplastic syndromes: Results of a single-center analysis.
    Müller-Berndorff H; Haas PS; Kunzmann R; Schulte-Mönting J; Lübbert M
    Ann Hematol; 2006 Aug; 85(8):502-13. PubMed ID: 16715299
    [TBL] [Abstract][Full Text] [Related]  

  • 12. International MDS risk analysis workshop (IMRAW)/IPSS reanalyzed: impact of cytopenias on clinical outcomes in myelodysplastic syndromes.
    Kao JM; McMillan A; Greenberg PL
    Am J Hematol; 2008 Oct; 83(10):765-70. PubMed ID: 18645988
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Factors influencing survival in myelodysplastic syndromes in a Brazilian population: comparison of FAB and WHO classifications.
    Lorand-Metze I; Pinheiro MP; Ribeiro E; de Paula EV; Metze K
    Leuk Res; 2004 Jun; 28(6):587-94. PubMed ID: 15120935
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Circulating myeloid colony-forming cells predict survival in myelodysplastic syndromes.
    Berer A; Jäger E; Sagaster V; Streubel B; Wimazal F; Sperr WR; Welterman A; Schwarzinger I; Frommlet F; Haas OA; Valent P; Lechner K; Geissler K; Ohler L
    Ann Hematol; 2003 May; 82(5):271-7. PubMed ID: 12739063
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Malignant tumors occurring after treatment of aplastic anemia. European Bone Marrow Transplantation-Severe Aplastic Anaemia Working Party.
    Socié G; Henry-Amar M; Bacigalupo A; Hows J; Tichelli A; Ljungman P; McCann SR; Frickhofen N; Van't Veer-Korthof E; Gluckman E
    N Engl J Med; 1993 Oct; 329(16):1152-7. PubMed ID: 8377778
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Myelodysplastic syndromes].
    Solary E; Fontenay M
    Rev Prat; 2010 Dec; 60(10):1408-9, 1412. PubMed ID: 21425540
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparison of hypoplastic myelodysplastic syndrome (MDS) with normo-/hypercellular MDS by International Prognostic Scoring System, cytogenetic and genetic studies.
    Huang TC; Ko BS; Tang JL; Hsu C; Chen CY; Tsay W; Huang SY; Yao M; Chen YC; Shen MC; Wang CH; Tien HF
    Leukemia; 2008 Mar; 22(3):544-50. PubMed ID: 18094713
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Refractory anemia in the elderly.
    Gardner FH
    Adv Intern Med; 1987; 32():155-75. PubMed ID: 3548248
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Evaluating the prognosis of patients with myelodysplastic syndromes.
    Aul C; Giagounidis A; Germing U; Ganser A
    Ann Hematol; 2002 Sep; 81(9):485-97. PubMed ID: 12373348
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Allogeneic bone marrow transplantation for myelodysplastic syndrome: outcomes analysis according to IPSS score.
    Appelbaum FR; Anderson J
    Leukemia; 1998 Sep; 12 Suppl 1():S25-9. PubMed ID: 9777891
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.